← Back to Search

Selective Serotonin Reuptake Inhibitor

brexpiprazole (0.5-2 mg) for Depression

Phase 3
Waitlist Available
Led By Sidney H Kennedy, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 8, week 16
Awards & highlights

Study Summary

This trial will replicate a study to assess if biomarkers can predict treatment response to standard antidepressants for patients with major depressive episodes.

Eligible Conditions
  • Depression

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 8, week 16
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 8, week 16 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mental Depression

Trial Design

2Treatment groups
Active Control
Group I: brexpiprazole (0.5-2 mg)Active Control1 Intervention
At week 8, participants classified as "non-responders" will be given 8 weeks of brexpiprazole as add-on treatment to escitalopram.
Group II: escitalopram (10-20 mg)Active Control1 Intervention
Participants are given escitalopram for 8 weeks. At week 8, participants will be assessed and classified as "responders" or "non-responders". Responders will continue on escitalopram until the study endpoint (16 weeks).

Find a Location

Who is running the clinical trial?

University of MichiganOTHER
1,795 Previous Clinical Trials
6,373,935 Total Patients Enrolled
67 Trials studying Depression
69,122 Patients Enrolled for Depression
University Health Network, TorontoLead Sponsor
1,468 Previous Clinical Trials
484,489 Total Patients Enrolled
52 Trials studying Depression
12,025 Patients Enrolled for Depression
BaycrestOTHER
43 Previous Clinical Trials
5,966 Total Patients Enrolled
2 Trials studying Depression
406 Patients Enrolled for Depression

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
The Journal of Clinical PsychiatryJournal
Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients with Major Depressive Disorder
Kennedy, Sidney H., Raymond W. Lam, Susan Rotzinger, Roumen V. Milev, Pierre Blier, Jonathan Downar, Kenneth R. Evans, et al.. 2019. “Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients with Major Depressive Disorder”. The Journal of Clinical Psychiatry. Physicians Postgraduate Press, Inc. doi:10.4088/jcp.18m12202.
BMC PsychiatryJournal
Discovering Biomarkers for Antidepressant Response: Protocol from the Canadian Biomarker Integration Network in Depression (CAN-BIND) and Clinical Characteristics of the First Patient Cohort
Lam, Raymond W., on behalf of the CAN-BIND Investigator Team, Roumen Milev, Susan Rotzinger, Ana C. Andreazza, Pierre Blier, Colleen Brenner, et al.. 2016. “Discovering Biomarkers for Antidepressant Response: Protocol from the Canadian Biomarker Integration Network in Depression (CAN-BIND) and Clinical Characteristics of the First Patient Cohort”. BMC Psychiatry. Springer Science and Business Media LLC. doi:10.1186/s12888-016-0785-x.
clinicaltrials.govStudy
Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study
Sidney Kennedy 2019. "Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04162522.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top